Anaplastic Large Cell Lymphoma (ALK+/ALK−): Difference between revisions
| [pending revision] | [pending revision] |
| Line 33: | Line 33: | ||
{| class="wikitable" | {| class="wikitable" | ||
|'''Signs and Symptoms''' | |'''Signs and Symptoms''' | ||
|Headache, seizures, nausea, fever, or a combination | |Headache, seizures, nausea, fever, or a combination | ||
|- | |- | ||
|'''Laboratory Findings''' | |'''Laboratory Findings''' | ||
| Line 61: | Line 61: | ||
|Negative (subset)||EXAMPLE CD4 | |Negative (subset)||EXAMPLE CD4 | ||
|} | |} | ||
==Chromosomal Rearrangements (Gene Fusions) ALK+ ALCL == | ==Chromosomal Rearrangements (Gene Fusions) ALK+ ALCL== | ||
Put your text here and fill in the table | Put your text here and fill in the table | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 71: | Line 71: | ||
!Notes | !Notes | ||
|- | |- | ||
|t(2;5)(p23;q35) ||''NPM1''::''ALK'' fusion | |t(2;5)(p23;q35)||''NPM1''::''ALK'' fusion | ||
|5' NPM1::3' ALK on der(5). constitutive activation of the catalytic domain of ALK. Kinase function activated by oligomerization of NPM1::ALK mediated by the NPM1 portion||EXAMPLE 30 to 50% of ALCL | |5' NPM1::3' ALK on der(5). constitutive activation of the catalytic domain of ALK. Kinase function activated by oligomerization of NPM1::ALK mediated by the NPM1 portion||EXAMPLE 30 to 50% of ALCL | ||
(COSMIC) | (COSMIC) | ||
| Line 125: | Line 125: | ||
|t(2;17)(p23;q23) | |t(2;17)(p23;q23) | ||
| | | | ||
| | |5'CLTC::3'ALK | ||
| | |very rare, one case reported | ||
| | | | ||
| | | | ||
| Line 132: | Line 132: | ||
| | | | ||
|- | |- | ||
|t(2;19)(p23; p13.1) | |t(2;19)(p23; p13.1) | ||
| | | | ||
|5'TPM4::3'ALK | |||
|very rare, one case reported | |||
| | | | ||
| | | | ||
| Line 202: | Line 202: | ||
| | | | ||
|- | |- | ||
| +7 found in 20% of cases | | +7 found in 20% of cases | ||
| | | | ||
| | | | ||